Key points are not available for this paper at this time.
Design
Review
Supports integrated CVD management across the continuum; leaves open questions on novel therapies in modern cohorts.
his is the second part of a 2-part article that presents a critical and comprehensive update of the current evidence for a cardiovascular disease (CVD) continuum based on the results of pathophysiological studies and the outcome of a broad range of clinical trials that have been performed in the past 15 years.In part I, we reviewed the current understanding of CVD pathophysiology and discussed data from clinical trials on subjects ranging from risk factors for disease through stable coronary artery disease (CAD).The present article continues the review of clinical trials, beginning with acute coronary syndromes (ACS) and continuing through extension of the concept of the CVD continuum to include stroke and renal disease.The article concludes with a discussion of areas in which future research might further clarify our understanding of the CVD continuum.
No takes yet. Share an insight, caveat, or question.
Dzau et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: